LEMPRELLIS
Live / Applied — Fifth extension granted (statement of use) (as of 24 Nov 2025)
What this means for you
Not registered yet, but its 27 Jun 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97477584
- Mark type
- Stylized text
- Filed
- 27 Jun 2022
- Published for opposition
- 31 Jan 2023
- Attorney of record
- Christopher M. Hanes
Goods and services
- Class 005 — Pharmaceuticals: Vaccines; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric and immune system related diseases and disorders
Owner
- Glaxo Group Limited, Stevenage, GB
- Glaxo Group Limited, Brentford, Middlesex, GB
Prosecution history
- 25 Nov 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 25 Nov 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 24 Nov 2025 — SOU EXTENSION 5 GRANTED
- 27 Sept 2025 — SOU EXTENSION 5 FILED
- 24 Nov 2025 — SOU EXTENSION 4 GRANTED
- 27 Mar 2025 — SOU EXTENSION 4 FILED
- 24 Nov 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 10 Oct 2025 — SOU EXTENSION RECEIVED WITH TEAS PETITION
- 10 Oct 2025 — NOTICE OF REVIVAL - E-MAILED
- 10 Oct 2025 — PETITION TO REVIVE-GRANTED
- 10 Oct 2025 — TEAS PETITION TO REVIVE RECEIVED
- 10 Oct 2025 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 10 Oct 2025 — ABANDONMENT - NO USE STATEMENT FILED
- 30 Sept 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 30 Sept 2024 — SOU EXTENSION 3 GRANTED